Next Edge Bio-Tech Plus Fund: Marketing Materials

Overview Investment Manager Marketing Materials Performance Commentary Regulatory

Fund Marketing Materials

Download Fund Profile

Download Fund Presentation

Media Contributions

May 6, 2016. Amber Kanwar, BNN – “Concordia Healthcare: Diving deep into claims of sky-high prices”

Television Appearances

Eden Rahim BNN Appearance

Eden Rahim On The line with BNN
Tues Jan 31^st 2017 “Eden Rahim, portfolio manager and options strategist, Next Edge Capital joins BNN to discuss U.S. President Donald Trump’s meeting with U.S. drug makers.”

Eden Rahim BNN Appearance

Eden Rahim BNN Appearance
Thurs Jan 2017 “Eden Rahim, portfolio manager and options strategist at Next Edge Capital, says the buying opportunity in late-stage biotech stocks is the best he’s ever seen. We talk valuations, takeover activity, drug discovery and Rahim’s top picks which include Acadia Pharmaceuticals, Portola Pharma and Neurocrine Bioscience.”

Rahim: Concordia, Valeant Are Structurally Broken

Eden Rahim Bloomberg TV Appearance
Fri Nov 11^th, 2016 “Eden Rahim, Portfolio Manager at Next Edge Capital joins Bloomberg TV Canada’s Mark Bunting to discuss what it will take to turn around Concordia and Valeant.”

Time to buy biotech and healthcare: The big call on stocks

Eden Rahim BNN Appearance
Mon Oct 31^st, 2016 “Eden Rahim, portfolio manager and options strategist, Next Edge Capital says weakness in the Healthcare sector of the market is a regular event just ahead of U.S. elections and provides an opportunity to buy.”

Canadian healthcare ‘bifurcated’: Big pharma struggling as small caps rally to new highs

Eden Rahim BNN Appearance
Wed Aug 3^rd, 2016
“Eden Rahim, Portfolio Manager and Options Strategist at Next Edge Capital joins BNN to discuss the current state of the biotech industry. He says that Canada’s healthcare market has been “bifurcated” this year, with big pharma companies like Valeant and Concordia “hogging the headlines” and innovative small-cap companies rallying to new highs.”

Potential Takeover Targets in Biotech

Eden Rahim BNN Appearance Tuesday Jun 21^st, 2016
“Takeover activity has been on the rise in biotech as the cost of bringing a new drug to market has soared. Eden Rahim, Manager of the Next Edge Bio-Tech Plus Fund, says M&A is an important aspect of biotech investing. Here are 15 companies in his Fund that he says are potential takeover targets. The top 3 candidates: Acadia, Intercept and Portola.”

Buying time in biotech: A lower risk approach

Eden Rahim BNN Appearance
Monday May 30^th, 2016

“Biotech stocks have been beaten lower after the past year and Eden Rahim, Portfolio Manager and Options Strategist, Next Edge Capital says investors should view the fall as a buying opportunity. He believes the market is undervalued and the big drop in the number of stocks below their 200 day moving average is represents a ‘low-risk entry signal.'”

Canadian Biotech in Focus: Risks and Opportunities

Eden Rahim BNN Appearance
Friday April 29^th, 2016
“We continue our focus on investing in biotech with Eden Rahim, Portfolio Manager and Options Strategist, Next Edge Capital. While acknowledging the risks involved in biotech, Rahim says the sector is recovering with “considerable room to run.” He also says ‘a genomic/gene-editing revolution is underway in biotech that is transforming drug development’.”

A Biotech Stock Picker’s Paradise

Eden Rahim BNN Appearance
Tuesday February 16^th, 2016
“Biotech stocks have been crushed to produce “the best valuations in years”, according to Eden Rahim, Portfolio Manager and Options Strategist, Next Edge Capital. Rahim says it’s a “biotech stock picker’s paradise.” He says you should focus on late-stage, cashed-up companies. Rahim’s top picks include: Acadia Pharmaceuticals, Medivation and Portola Pharmaceuticals.”

The Daily Brief

Eden Rahim Bloomberg TV Appearance
Thursday January 21^st, 2016
“With the World Economic Forum in full swing, The Daily Brief looks at where large investors are putting their money in volatile markets, oil’s collapse and the potential for a long-term bull market in biotech stocks.”

CDN Biotech: Underinvested with Lots of Opportunity

Eden Rahim BNN Appearance
Friday December 4^th, 2015
“Eden Rahim, Portfolio Manager and Options Strategist, Next Edge Capital says the biotech sector in Canada is vastly underinvested and it contains a lot of opportunity. Rahim – who manages the Next Edge Bio-Tech Plus Fund – says the Bull Market in Biotech has plenty of room to run higher and he’s amazed that it took “so long” for the market to wake-up to signs of trouble in the business model at Valeant.”

DISCLAIMERThe ‘Next Edge Bio-Tech Plus Fund’ or ‘Fund’ means the ‘Next Edge Bio-Tech Plus Fund’. Capitalized terms not defined in this presentation are defined as set forth in the prospectus of the Fund (the ‘Prospectus’). This communication is not, and under no circumstances is to be construed as, an invitation to make an investment in the Fund nor does it constitute a public offering to sell the Fund or any other products described herein. Applications for the Fund will only be considered on the terms of the Prospectus. Each purchaser of the units (the ‘Units’) may have statutory or contractual rights of action under certain circumstances as disclosed in the Prospectus. Please review the provisions of the applicable securities legislation for particulars of these rights.. Terms defined herein shall have the same meaning as in the Prospectus. Potential investors should note that alternative investments can involve significant risks and the value of an investment may go down as well as up. There is no guarantee of trading performance and past or projected performance is not indicative of future results. Investors should review the Prospectus in its entirety for a complete description of the Fund, its risks, and consult their registered dealers before making an investment. The information contained in this material is subject to change without notice and Next Edge Capital Corp. will not be held liable for any inaccuracies or misprints. The Fund has not been and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States. The Fund may not be offered or sold in the United States or to US persons. Any descriptions or information involving investment process or strategies is provided for illustration purposes only, may not be fully indicative of any present or future investments, may be changed at the discretion of the Investment Manager and are not intended to reflect performance. The following does not purport to be a complete summary of all of the risks associated with an investment in the Fund. Please see the Fund’s Prospectus for a complete listing and description of the risks associated with an investment in the Fund. The Fund is generally exposed to the following risks: Biotechnology Risk; Derivatives Risk; Equity Securities Risk; FACTA Risk; Foreign Currency Risk; Foreign Securities Risk; Legislation and Litigation Risk; Liquidity Risk; Multiple Class Risk; Options Risk; Sector Risk; Stock Market Risk; Substantial Securityholder Risk.